Economic Valuation

Read More | No Comments

Regulatory Science Lab

Economic Valuation

Research on the value, affordability, cost-effectiveness, and resource implications of precision medicine and emerging health technologies.

2025

  1. Cupples G, Krebs E, Weymann D, Ho C, Regier DA. Adopting life-cycle HTA: A tumor-agnostic precision oncology index economic evaluation from publicly available reimbursement reviews. International Journal of Technology Assessment in Health Care. 2025; 41(1):e41.

2024

  1. Pataky RE, Bryan S, Sadatsafavi M, Peacock S, Regier DA. Using genomic heterogeneity to inform therapeutic decisions for metastatic colorectal cancer: An application of the value of heterogeneity framework. Applied Health Economics and Health Policy. 2025; 23(3):441–452.
  2. Weymann D, Buckell J, Fahr P, Loewen R, Ehman M, Pollard S, Friedman JM, Stockler-Ipsiroglu S, Elliott AM, Wordsworth S, Buchanan J, Regier DA. Health care costs after genome-wide sequencing for children with rare diseases in England and Canada. JAMA Network Open. 2024; 7(7):e2420842:1–15.
  3. Pollard S, Chan B, Gerrie AS, Raymakers AJN, Regier DA. Assay-guided treatment sequencing in chronic lymphocytic leukemia: A cost-effectiveness analysis. Scientific Reports. 2024; 14(1):e17294:1–8.
  4. Ehman M, Punian J, Weymann D, Regier DA. Next-generation sequencing in oncology: Challenges in economic evaluation. Expert Review of Pharmacoeconomics & Outcomes Research. 2024; (10):1115–1132.

2023

  1. Weymann D, Pollard S, Lam H, Krebs E, Regier DA. Toward best practices for economic evaluations of tumour-agnostic therapies: A review of current barriers and solutions. Value in Health. 2023; 26(11):1608–1617.

2022

  1. Pataky R, Bryan S, Sadatsafavi M, Peacock P, Regier DA. Tools for the economic evaluation of precision medicine: A scoping review of frameworks for valuing heterogeneity-informed decisions. PharmacoEconomics. 2022; 40(10):931–941.
  2. Pollard S, Weymann D, Chan B, Ehman M, Wordsworth S, Buchanan J, Hanna TP, Ho C, Lim HJ, Lorgelly PK, Raymakers A, McCabe C, Regier DA. Defining a core data set for the economic evaluation of precision oncology. Value in Health. 2022; 25(8):1371–1380.
  3. Regier DA, Chan B, Costa S, Scott DW, Steidl C, Connors JM, Karsan A, Marra MM, Kridel R, Cromwell I, Pollard S. Cost-effectiveness of molecularly guided treatment in diffuse large B-cell lymphoma in patients under 60. Cancers. 2022; 14(4):1–15.
  4. Weymann D, Laskin J, Jones SJM, Roscoe R, Lim HJ, Renouf DJ, Schrader KA, Sun S, Yip S, Marra MA, Regier DA. Early-stage economic analysis of research-based comprehensive genomic sequencing for advanced cancer care. Journal of Community Genetics. 2022; 13(5):523–538.

2021

  1. Chan KKW, Cheung MC, Regier DA, Hay A, Louie AV, Cheung WY, Tarride JE, Udayakumar, Mittman N. The past, present, and future of economic evaluations of precision medicine at the Committee for Economic Analyses of the Canadian Cancer Trials Group. Current Oncology. 2021; 28(5):3649–3658.
  2. Raymakers AJN, Cameron D, Tyldesley S, Regier DA. Cost-effectiveness analysis of stereotactic ablative body radiotherapy for the treatment of oligometastatic tumors versus standard of care. Current Oncology. 2021; 28(3):1857–1866.
  3. Seixas BV, Regier DA, Bryan S, Mitton C. Describing practices of priority setting and resource allocation in publicly funded health care systems of high-income countries. BMC Health Services Research. 2021; 21(1):90.
  4. Weymann D, Dragojlovic N, Pollard S, Regier DA. Allocating healthcare resources to genomic testing in Canada: Latest evidence and current challenges. Journal of Community Genetics. 2021; 13(5):467–476.

2020

  1. Raymakers A, Costa S, Cameron D, Regier DA. Cost-effectiveness of brentuximab vedotin in advanced-stage Hodgkin’s lymphoma: A probabilistic analysis. BMC Cancer. 2020; 20(1):1–9.